{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Norway Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/no/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/no/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Norway, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:c3e1ff601bfb52275039cfaf8e6dc2899264c68c4b08e28826f4849b242f631f", "url": "https://finance.yahoo.com/healthcare/articles/photocure-welcomes-fda-proposal-initiate-162200526.html", "external_url": "https://finance.yahoo.com/healthcare/articles/photocure-welcomes-fda-proposal-initiate-162200526.html", "title": "Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II", "content_text": "OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended as an aid for the detection of bladder cancer from Class III to Class II. Importantly, FDA is initiating the proposed reclassification on its own initiative following its review of available scientific, clinical and post-market evidence. FDA states that there is sufficient information to establish special contr", "date_published": "2026-08-14T16:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "PHO"], "_sharemaestro": {"country": "Norway", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHO", "name": "Photocure ASA", "sentiment_url": "https://sharemaestro.com/sentiment/049f1fbf-cbea-416f-8535-8ec14795345c/"}]}}]}